Form D · Biotechnology

XiltriX North America, LLC

San Diego, CA · CIK 0001777611

Offering snapshot reported Aug 26, 2026 · SEC filing

Reported sold
$3M
Offering amount: $3M
Investors reported
20
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 13, 2026
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 26, 2026Initial$3,000,000No comparison20SEC filing
Dec 9, 2024Initial$2,110,653No comparison18SEC filing
Feb 14, 2024Initial$2,499,999No comparison18SEC filing
Feb 1, 2023Initial$2,760,711No comparison15SEC filing
Nov 29, 2021Initial$3,750,000No comparison12SEC filing
Sep 23, 2020Initial$4,275,000No comparison10SEC filing
May 29, 2019Amendment$4,200,000$0vs May 24, 201911SEC filing
May 24, 2019Initial$4,200,000No comparison11SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-595436

Source: Form D, filed Aug 26, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Moises Eilemberg Director, Executive
Hendrik Hanselaar Director
Doron Lurie Director
Michael O'connell Director
Nathaniel Paige Director
Stephen Tierney Executive
Erik Van Stek Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
9255 Towne Center Drive Suite 925
San Diego, CA, 92121
Phone: 858-208-0368